Do GLP-1s Change Your Personality? What the Mood Science Says

GLP-1 receptors are found in the brain as well as the gut. Here is what the research does and does not show about mood, motivation and the "Ozempic personality" people keep describing.

TL;DR: GLP-1 receptors sit in brain areas linked to reward, mostly mapped in animal studies. The largest trial analysis found no increase in psychiatric side effects, and US and EU regulators found no link to suicidal thoughts. A few published case reports describe people who felt flat or lost interest in things. The evidence is thin, so notice how you feel and tell your prescriber about any change.

This article is journalism, not medical advice. Questions about your own medicine belong with your prescriber.

Ask anyone on a GLP-1 and the first thing they often mention is the quiet: the constant negotiation with food goes down. But a second story keeps coming up, a sense that something else changed too. Less interest in a glass of wine. A flatter mood, or a new calm. People call it the "Ozempic personality", and a psychiatrist writing in Psychology Today asked the question directly: do these drugs change who you are? [1]

It is an unsettling thing to feel. You started a medicine to change your relationship with food, and you may be noticing changes in how you feel about other things too. That is worth taking seriously. It is also worth knowing what the evidence can and cannot tell you yet.

Key Takeaways

• GLP-1 receptors are found in brain areas tied to reward and motivation. Most of that research is in animals, and human brain-imaging results are inconsistent. [2]
• Across 80 placebo-controlled trials with more than 107,000 people, GLP-1 medicines were not linked to more psychiatric side effects, and mental-health quality of life improved on average. [3]
• The FDA and the European Medicines Agency both concluded the evidence does not show these medicines cause suicidal thoughts. [4][5]
• Feeling flat or losing interest has been described in a handful of published case reports, not in large studies. Nobody knows yet how common it is or why it happens. [6][7][8]
• Any change in mood, motivation or interest in things you enjoy is worth raising with your prescriber.

The medication was never only about your stomach

It is tempting to picture a GLP-1 working only in the gut. But the receptors it acts on are also found in the brain. A 2026 systematic review describes them as "widely expressed in the hypothalamus, VTA, and NAc", areas involved in reward and motivation. [2] In that research, switching these receptors on reduced the rewarding pull of tasty food, alcohol and stimulants.

Two cautions come with that picture. Most of it comes from animal studies: the same review found only five human studies, and it notes that human brain-imaging results "report inconsistent effects". [2] The Washington Post reported in May 2026 that scientists say these drugs "may be reshaping the brain" [9], and that is the open question, not a settled answer.

For alcohol, there is one small human trial. In a nine-week study of adults with alcohol use disorder, low-dose semaglutide reduced craving and some drinking outcomes. The authors called it "initial prospective evidence" that justifies larger trials. [10] It does not tell us what happens to everyday enjoyment in people taking the medicine for weight.

What people are actually noticing

The accounts fall roughly into three groups.

The quieting. Fewer urges, a calmer baseline. The large trial analysis points the same way on average: GLP-1 treatment was linked to less emotional eating and better mental-health quality of life. [3]

The flattening. This is the one to watch most closely. A psychiatrist writing in Psychology Today described reports of "lack of drive, emotional blunting, inability to feel pleasure" in people's usual pursuits. [1] Doctors call this anhedonia. It has appeared in a small number of published case reports. In a 2026 series of three patients on tirzepatide, one said she felt "flat", and said it felt different from an earlier depression; another reported "loss of interest in her other hobbies". After their clinicians lowered the dose, the authors report that two had a "marked improvement in motivation and enjoyment of daily activities". [6] Two earlier cases on semaglutide describe "decreased interest and motivation" that improved after the medicine was stopped. [7] Each report's authors say the same thing: a few cases can raise a question but cannot answer it. [6][7][8]

The identity question. The subtler one: if I want less, am I still me? When a lot of life has been organized around food, its retreat can feel like losing a companion, even an unwelcome one.

Many people notice none of these. Naming them still helps, because a shift you can name is easier to bring to someone.

Why the science is early

The research points in different directions. Large trials find no rise in psychiatric side effects. [3] Yet a handful of individual cases describe the opposite experience. [6][7][8] One review even suggests these drugs could reduce anhedonia, not cause it. [11] Studies are also still separating what the medicine does directly from what follows from eating less and a changing body.

The regulators' conclusions are specific. In 2024 the EMA's safety committee found the evidence "does not support a causal association" with suicidal thoughts. [5] In January 2026 the FDA, after analyzing 91 trials, reported that the results did not show an increased risk of suicidal thoughts or behavior, or of other relevant psychiatric side effects, and asked drugmakers to remove that warning from the labels of three weight-loss medicines. [4] Trial averages describe groups, though, not any one person. That is why your own experience still counts as information.

What to watch for in yourself

You don't need to monitor yourself anxiously. A few questions are worth asking now and then:

• Has your interest in things you used to love quietly dimmed?
• Is your mood flatter, or more anxious, than before you started?
• Do the changes feel like relief, or like absence?

Noting how you feel alongside your doses, as you might with mood changes and anxiety on GLP-1s, turns a vague worry into a pattern you can see. To tell appetite changes apart from mood changes, a food-noise assessment can help.

The FDA's advice is plain: "Tell your health care professional if you experience new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior." [4] If you're thinking about changing anything, talk to your prescriber first. If you have thoughts of harming yourself, in the US call or text 988, the Suicide and Crisis Lifeline, which is available 24/7 [12]. Elsewhere, call your local emergency number.

What this means for you

A medicine that reaches the brain is not automatically a reason for alarm, and it is not a reason to dismiss what you feel either. The best evidence so far is reassuring on average. The reports of flatness are few and unexplained. Both can be true at once.

What helps is noticing what changes, putting words to it, and taking those words to the people treating you. That is also not the easy way out that the stigma around GLP-1s claims it is.

Matt curates the week's most interesting GLP-1 research so you don't have to dig for it. Get curated GLP-1 research weekly, honest and never hype.

Sources

1. Hebert C. "Do GLP-1's Change Your Personality?" Psychology Today (blog, Health Examined), updated 4 June 2026. https://www.psychologytoday.com/us/blog/health-examined/202606/do-glp-1s-change-your-personality
2. Edwiges M, et al. "Nucleus accumbens GLP-1 signaling and its role in reward and metabolic regulation: a systematic review." Frontiers in Neuroanatomy, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13422549/
3. Pierret ACS, et al. "Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis." JAMA Psychiatry, 2025. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2833558
4. US FDA. "FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications," 13 January 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
5. European Medicines Agency. "Meeting highlights from the PRAC, 8–11 April 2024." https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
6. Nadolsky S, et al. "Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series." Obesity Pillars, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13382402/
7. Li J-R, et al. "Case Report: Semaglutide-associated depression: a report of two cases." Frontiers in Psychiatry, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10495976/
8. Alanazi AS, Alanazi BA. "Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus." Frontiers in Psychiatry, 2026. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1893173/full
9. The Washington Post. "Ozempic may be reshaping the brain, scientists say," 28 May 2026. https://www.washingtonpost.com/health/2026/05/28/ozempic-may-be-reshaping-brain-scientists-say/
10. Hendershot CS, et al. "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial." JAMA Psychiatry, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/
11. Krupa AJ. "Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry." Neuroscience Applied, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12244148/
12. 988 Suicide & Crisis Lifeline. https://988lifeline.org/